

FDA-APPROVED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENTS

Generic	Brand	Strength	Form	Usual Dose
ANGIOGENESIS INHIBITOR				
bevacizumab	Avastin	100mg, 400mg	soln for IV infusion after dilution	15mg/kg once every 3wks with carboplatin/paclitaxel
ramucirumab	Cyramza	10mg/mL	soln for IV infusion after dilution	10mg/kg on Day 1 of a 21-day cycle prior to docetaxel; continue until disease progression or unacceptable toxicity
ANTIMETABOLITES				
gemcitabine	Gemzar	200mg, 1g	pwd for IV infusion after reconstitution	1000mg/m ² on Days 1, 8, and 15 of each 28 day cycle; or 1250mg/m ² on Days 1 and 8 of each 21 day cycle
methotrexate	—	25mg/mL	soln for IV, IM, intra-arterial, or intrathecal administration after dilution	See drug entry and manufacturer's literature
		1g	pwd for IV, IM, intra-arterial, or intrathecal administration after dilution	
	Trexall	5mg, 7.5mg, 10mg, 15mg	scored tabs	
pemetrexed	Alimta	100mg, 500mg	pwd for IV inj after reconstitution and dilution	500mg/m ² on Day 1 of each 21-day cycle
ANTIMICROTUBULE AGENTS				
docetaxel	Taxotere	40mg/mL	soln for IV infusion after dilution	75mg/m ² once every 3wks
paclitaxel	Taxol	6mg/mL	soln for IV infusion after dilution	135mg/m ² IV plus cisplatin every 3wks
paclitaxel [bound to albumin (human)]	Abraxane	100mg/vial	pwd for IV infusion after reconstitution	100mg/m ² on Days 1, 8, and 15 of each 21-day cycle
vinorelbine	Navelbine	10mg/mL	soln for IV inj after dilution	<i>Monotherapy:</i> 30mg/m ² once weekly <i>Combination therapy:</i> 25mg/m ² once weekly given every 4wks; or 30mg/m ² once weekly given on Days 1 and 29, then every 6wks
PD-1 BLOCKING ANTIBODY				
nivolumab	Opdivo	10mg/mL	soln for IV infusion after dilution	3mg/kg every 2wks until disease progression or unacceptable toxicity
PHOTOSENSITIZING AGENT				
porfimer	Photofrin	75mg	pwd for IV inj after reconstitution	2mg/kg then illumination with laser light 40–50hrs following injection
TYROSINE KINASE INHIBITORS				
afatinib	Gilotrif	20mg, 30mg, 40mg	tabs	40mg once daily on empty stomach
ceritinib	Zykadia	150mg	hard gel caps	750mg once daily until disease progression or unacceptable toxicity
crizotinib	Xalkori	200mg, 250mg	caps	250mg twice daily
erlotinib	Tarceva	25mg, 100mg, 150mg	tabs	150mg once daily
gefitinib	Iressa*	250mg	tabs	250mg once daily until disease progression or unacceptable toxicity

NOTES

* For NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations only.

Not an inclusive list of medications, official indications, and/or dosing details. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 11/2015)